Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome.
about
DNA Methylation and Chromatin Remodeling: The Blueprint of Cancer EpigeneticsNovel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic)Childhood acute myeloid leukaemiaMechanisms of Histone Deacetylase Inhibitor-Regulated Gene Expression in Cancer CellsHistone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancyCytoprotection "gone astray": Nrf2 and its role in cancerPanobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51Panobinostat in lymphoid and myeloid malignancies.Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara studyPhase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia.Emerging therapies for acute myeloid leukemia.Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.The histone deacetylase inhibitor SAHA acts in synergism with fenretinide and doxorubicin to control growth of rhabdoid tumor cells.Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinicHDAC inhibitors repress BARD1 isoform expression in acute myeloid leukemia cells via activation of miR-19a and/or b.Suberoylanilide hydroxamic acid induces hypersensitivity to radiation therapy in acute myelogenous leukemia cells expressing constitutively active FLT3 mutants.Immunosuppressive Glycodelin A is an independent marker for poor prognosis in endometrial cancer.Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemiaA phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia.Epigenetics in diagnosis, prognostic assessment and treatment of cancer: an update.Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.Histone Deacetylase Inhibitors Target the Leukemic Microenvironment by Enhancing a Nherf1-Protein Phosphatase 1α-TAZ Signaling Pathway in OsteoblastsVorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas.HDAC Inhibition Induces MicroRNA-182, which Targets RAD51 and Impairs HR Repair to Sensitize Cells to Sapacitabine in Acute Myelogenous LeukemiaHistone deacetylases 1 and 2 cooperate in regulating BRCA1, CHK1, and RAD51 expression in acute myeloid leukemia cells.Novel therapies for children with acute myeloid leukaemia.Rhabdoid tumors: clinical approaches and molecular targets for innovative therapy.Relapsed and refractory pediatric acute myeloid leukemia: current and emerging treatments.Strategies to modulate heritable epigenetic defects in cellular machinery: lessons from nature.Overview of therapy and strategies for optimizing outcomes in de novo pediatric acute myeloid leukemia.Deacetylase inhibitors for the treatment of myelodysplastic syndromes.Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.Reversible inhibitors of LSD1 as therapeutic agents in acute myeloid leukemia: clinical significance and progress to date.New treatment for acute myelogenous leukemia.Emerging approaches for histone deacetylase inhibitor drug discovery.Epigenetic Therapy in Acute Myeloid Leukemia: Current and Future Directions.Secondary Adult Acute Myeloid Leukemia: a Review of Our Evolving Understanding of a Complex Disease Process.Histone Deacetylase Inhibitors as Anticancer Drugs.Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
P2860
Q26749421-E2C72937-A016-4D88-9F8E-7D2E079BA13AQ26770391-3218C5C5-84D8-4308-80D9-7E0ABBA4FD06Q27005960-7A4694E9-6F20-473C-A0E0-37A6B49B804DQ27015931-9807DF9D-028D-4B68-8834-3EC8D792FE60Q28082536-F5112877-EF63-47BE-BDCC-E06E19BCEC02Q28393784-A37277FB-C383-4ED8-8D98-38D88890C85AQ28535006-09237757-1D84-49EC-BA68-CBC5C2CF3C2DQ33408889-AD1E2316-5BBA-4C50-907B-5A6F7A97A324Q33424306-DC68C3A9-6FFD-4C50-A7A6-7AF97219DB89Q33437992-18C3DABB-C027-4428-B520-D1C27E77A918Q33576363-4ED7EBA0-71A2-4D4A-B6EE-4B54549E4041Q33983255-11ABF47A-47A9-403F-ABF7-960B73A0318BQ34350209-259E9115-1EAF-4F41-922C-C17BF3984FABQ34771550-B30FD654-9098-4A4F-B9CB-B4F6497B8D26Q34817365-D8B212CB-8DE1-42A9-AC01-FD3E68806D16Q35070712-8909E21F-27AA-4D86-9A19-8B50BB933C6BQ35075792-8A39BA16-A1B6-4511-A4CE-315580A063F1Q35078816-19EDCCC1-7DE5-403B-B09A-BF50371FFC5CQ35096240-A6BC51D6-D32E-4824-BF82-2DCC9FB0C9D2Q35327711-16B4BD0F-1BA4-42A5-877E-2C010E6553E6Q35726371-DE2642C1-49F7-4A71-A9F3-0C9AAB005B37Q36242646-9838F770-C469-4124-B92A-33433941D569Q36444091-A99D476A-8D17-4D6D-B325-C6A3B25E95AFQ36660672-0557A1C3-286C-422C-BB82-8578D1097DA0Q37100102-EFDCBEAC-95FB-4869-940D-BC4A5F530AF5Q37701599-EE29C3C3-A911-4E41-BBEA-0E40FBED50B5Q38096798-4EE2A984-0916-4F14-A1A7-32105A66B917Q38121136-B1862120-D363-49A1-B479-BC888A8F786FQ38155455-51F7D4E9-C0B6-427E-A204-72EA185D50C0Q38166178-719F3FFE-8238-41AB-A0F1-29732EB23072Q38196743-E31C2F1C-312A-4999-A04E-D530C90B9EA9Q38233492-2B57A689-6858-4913-97AD-BF56629EBA4AQ38240733-1C1BE46F-5BAE-4D6C-9149-D1DD87817583Q38270780-6BA169D0-7F52-4C4E-A75E-654D3B4BB48BQ38284045-95C5AEDE-85DD-4D2D-948C-55B31E1383F3Q38431356-9CB4FE2E-4284-4416-BE24-91A6BF46EAADQ38537883-03EBCFF6-6EBF-40F4-9DD7-593D170BE607Q38542828-49436F18-485E-4BC6-A085-091B80507F26Q38696932-DF9ED1B3-8EB4-45F0-9E69-7DACE84A3EECQ38710509-6DD45ECD-1723-452A-8953-EC5D90BF400F
P2860
Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Phase II trial of vorinostat w ...... a or myelodysplastic syndrome.
@en
type
label
Phase II trial of vorinostat w ...... a or myelodysplastic syndrome.
@en
prefLabel
Phase II trial of vorinostat w ...... a or myelodysplastic syndrome.
@en
P2093
P2860
P50
P356
P1476
Phase II trial of vorinostat w ...... a or myelodysplastic syndrome.
@en
P2093
Deborah McCue
Francesco Paolo Tambaro
Marcos de Lima
Marina Y Konopleva
Mark Brandt
Nebiyou B Bekele
Sherry R Pierce
Tapan M Kadia
Willie Mae Newsome
P2860
P304
P356
10.1200/JCO.2011.38.3265
P407
P50
P577
2012-05-14T00:00:00Z